Lead Time of the Methotrexate Establishment and Vaccinal Protection Against the Pneumococcal Agent in Patients Affected With Rheumatoid Polyarthritis
Phase of Trial: Phase III
Latest Information Update: 21 Feb 2018
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary) ; Pneumococcal vaccine
- Indications Pneumococcal infections
- Focus Pharmacodynamics; Registrational
- Acronyms VACIMRA
- 31 Aug 2015 Planned End Date changed from 1 Sep 2016 to 1 Mar 2018 as per ClinicalTrials.gov record.
- 31 Aug 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Apr 2017 as per ClinicalTrials.gov record.
- 08 Jan 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.